Research programme: MYC oncoprotein modulators - Avalon
Alternative Names: MYC inhibitors - AvalonLatest Information Update: 19 Aug 2008
At a glance
- Originator Avalon Pharmaceuticals
- Class
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Aug 2008 Discontinued for Cancer in USA (unspecified route)
- 22 Feb 2007 Early research in Cancer in USA (unspecified route)